154 related articles for article (PubMed ID: 15648054)
1. CYP2D6 and CYP1A1 mutations in the Turkish population.
Aydin M; Hatirnaz O; Erensoy N; Ozbek U
Cell Biochem Funct; 2005; 23(2):133-5. PubMed ID: 15648054
[TBL] [Abstract][Full Text] [Related]
2. Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias.
Aydin-Sayitoglu M; Hatirnaz O; Erensoy N; Ozbek U
Am J Hematol; 2006 Mar; 81(3):162-70. PubMed ID: 16493615
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms in CYP1A1, CYP2D6, UGT1A6, UGT1A7, and SULT1A1 genes and correlation with benzene exposure in a Chinese occupational population.
Gu SY; Zhang ZB; Wan JX; Jin XP; Xia ZL
J Toxicol Environ Health A; 2007 Jun; 70(11):916-24. PubMed ID: 17479406
[TBL] [Abstract][Full Text] [Related]
4. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
Chen HC; Hu WX; Liu QX; Li WK; Chen FZ; Rao ZZ; Liu XF; Luo YP; Cao YF
Eur J Cancer Prev; 2008 Jun; 17(3):251-8. PubMed ID: 18414197
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
7. [Cytochrome P450*2D6 gene polymorphism in Chinese population].
Tao E; Liu Z; Chen B; Pan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Feb; 15(1):34-7. PubMed ID: 9456373
[TBL] [Abstract][Full Text] [Related]
8. [Genetic polymorphism of CYP-1A1, CYP2D6 and risks of chronic benzene poisoning].
Gu SY; Zhang ZB; Cao DZ; Wan JX; Gao XL; Jin XP; Xia ZL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 May; 24(5):266-9. PubMed ID: 16737584
[TBL] [Abstract][Full Text] [Related]
9. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract][Full Text] [Related]
10. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
13. Real-time genotyping of cytochrome P4501A1 A4889G and T6235C polymorphisms.
Harth V; Brüning T; Abel J; Koch B; Berg I; Sachinidis A; Bolt HM; Vetter H; Ko Y
Mol Cell Probes; 2001 Apr; 15(2):93-7. PubMed ID: 11292327
[TBL] [Abstract][Full Text] [Related]
14. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay.
Labuda D; Krajinovic M; Richer C; Skoll A; Sinnett H; Yotova V; Sinnett D
Anal Biochem; 1999 Nov; 275(1):84-92. PubMed ID: 10542112
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
17. CYP1A1 alleles in female genital cancers in the Polish population.
Seremak-Mrozikiewicz A; Drews K; Semczuk A; Jakowicki JA; Mrozikiewicz PM
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):246-50. PubMed ID: 15653213
[TBL] [Abstract][Full Text] [Related]
18. Frequency of mutated allele CYP2D6*4 in the Turkish population.
Koseler A; Ilcol YO; Ulus IH
Pharmacology; 2007; 79(4):203-6. PubMed ID: 17374963
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population.
Silig Y; Pinarbasi H; Günes S; Ayan S; Bagci H; Cetinkaya O
Cancer Invest; 2006 Feb; 24(1):41-5. PubMed ID: 16466991
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
Srivastava DS; Mandhani A; Mittal RD
Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
